High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors

• Published in: Journal of medicinal chemistry 2006-12, Vol.49 (25), p.7440-7449
• Main Authors: Dell'Agli, Mario, Parapini, Silvia, Galli, Germana, Vaiana, Nadia, Taramelli, Donatella, Sparatore, Anna, Liu, Peng, Dunn, Ben M, Bosisio, Enrica, Romeo, Sergio
• Format: Article
• Language: English
• Subjects: Aminoquinolines - chemical synthesis; Aminoquinolines - pharmacology; Aminoquinolines - toxicity; Animals; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimalarials - chemical synthesis; Antimalarials - pharmacology; Antimalarials - toxicity; Antiparasitic agents; Aspartic Acid Endopeptidases - antagonists & inhibitors; Biological and medical sciences; Cathepsin D - antagonists & inhibitors; Cells, Cultured; Dipeptides - chemical synthesis; Dipeptides - pharmacology; Dipeptides - toxicity; Drug Resistance; Fibroblasts - drug effects; Humans; Leucine - analogs & derivatives; Leucine - chemical synthesis; Leucine - pharmacology; Leucine - toxicity; Medical sciences; Models, Molecular; Pharmacology. Drug treatments; Plasmodium falciparum - drug effects; Plasmodium falciparum - enzymology; Protozoan Proteins; Stereoisomerism; Structure-Activity Relationship
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm061033d

The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the “double-drug” approach:  primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 μM was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2−20 μM). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K i = 1−700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 μM and were highly selective for PLMs vs human cathepsin D.